- Home
- CREV vs XRTX Comparison
CREV vs XRTX Comparison
Compare CREV & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CREV | XRTX |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | Australia | Canada |
| Employees | N/A | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CREV | XRTX |
|---|---|---|
| Price | $1.66 | $0.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.2K | ★ 53.3K |
| Earning Date | 01-01-0001 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,677,475.00 | N/A |
| Revenue This Year | $40.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 86.77 | N/A |
| 52 Week Low | $1.48 | $0.52 |
| 52 Week High | $12.75 | $1.79 |
Technical Indicators
Market Signals| Indicator | CREV | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.93 | 47.01 |
| Support Level | $1.64 | $0.61 |
| Resistance Level | $2.85 | $0.67 |
| Average True Range (ATR) | 0.24 | 0.03 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 17.20 | 62.68 |
Price Performance
Historical ComparisonAbout CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.